133TiP: A randomized phase III study of ivonescimab versus pembrolizumab as first-line treatment of metastatic non-small cell lung cancer as first-line treatment of metastatic non-small cell lung cancer with high tumor PD-L1 expression: HARMONi-7
Antonio Passaro(European Institute of Oncology), Antonio Calles(Dana-Farber Cancer Institute), N. Girard(Université de Versailles Saint-Quentin-en-Yvelines), Chirag D. Gandhi, Jason Agulnik, Patricia M. McGovern(University of Minnesota), McQuinn Gumus(Istanbul Medeniyet University), D. Rodriguez Abreu(Universidad de Las Palmas de Gran Canaria), P. Paik(Memorial Sloan Kettering Cancer Center), D. Berz(Los Angeles Clinical Trials), N. Vokes(The University of Texas MD Anderson Cancer Center), Bing Wang(Chinese Academy of Sciences), Yi‐Long Wu(Guangdong Academy of Medical Sciences), Xin Bai(Harbin Medical University), Joseph B. Weiss(University of North Carolina Health Care), Konstantinos Syrigos(National and Kapodistrian University of Athens), R. Ramlau(Poznan University of Medical Sciences), E. Santos(Oncology Institute of Hope and Innovation), Julia Rotow(University of California, San Francisco)
Cited by 1
Related Papers
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k